In order to proactively address areas of concern to the FDA and other regulators, All units within each pharmaceutical firm should review recent regulatory observations and proactively establish programs or systems to address the regulatory concerns.
FDA 483 Observations in the Laboratory. What went wrong? How can they be avoided? - Webinar By GlobalCompliancePanel
10 January 2012, Wilmington, United States
Introduction
Venue
online training
online training, DE, 1000 N West Street, Wilmington, 19801, United States
Useful links
Organised by
GlobalCompliancePanel
Contact information
Related events
TAC 2025 - 60th Anniversary Conference
14 April 2025 09:00 - 16 April 2025 17:00, Guildford, United Kingdom
What's in that Perfume? - The Chemistry behind an iconic Christmas gift
3 December 2024 18:00-20:00, London, United Kingdom
Chemistry Teaching in Practice
9 January 2025 09:30-16:00, Oxford, United Kingdom
Joint SoBRA / UUÂãÁÄÖ±²¥ Winter Conference 2024 Current Issues in Contaminated Land Risk Assessment
10 December 2024 09:45-18:00, London, United Kingdom
Search
Advertisement
Spotlight
Explore
Membership
